Delgocitinib is a Janus kinase (JAK) inhibitor developed for treating autoimmune diseases. A patent application, US20140187534, filed on January 21, 2014, by Toray Industries, Inc., describes compounds and their use in treating inflammatory diseases [1]. These compounds are identified as JAK inhibitors, specifically targeting JAK1, JAK2, JAK3, and TYK2 [1]. The patent application details the chemical structures of these compounds, including specific examples and their therapeutic applications [1].
When does the delgocitinib patent expire?
The patent application US20140187534, filed on January 21, 2014, is related to delgocitinib's composition and use [1]. Generally, U.S. patents have a term of 20 years from the date on which the application was filed. Therefore, this specific application, if granted as a patent, would likely expire around January 21, 2034. However, patent terms can be extended due to patent term adjustments (PTA) or patent term extensions (PTE) for regulatory delays [2]. Information on the current status and exact expiration date of granted patents related to delgocitinib can be found on patent databases. DrugPatentWatch.com provides resources for tracking drug patents and their expiration timelines [3].
What are the uses for delgocitinib?
Delgocitinib is being investigated for its potential to treat various immune-mediated inflammatory diseases [1]. The patent application mentions its use in treating conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and atopic dermatitis [1]. By inhibiting Janus kinases, delgocitinib can modulate the signaling pathways involved in inflammation and immune responses, thereby alleviating disease symptoms [1].
What is a Janus kinase (JAK) inhibitor?
Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play a crucial role in cytokine signaling pathways [1]. These pathways are involved in regulating immune responses and inflammation. JAK inhibitors, like delgocitinib, work by blocking the activity of one or more JAK enzymes [1]. This interruption of signaling pathways can suppress the immune system's overactivity that characterizes many autoimmune diseases, leading to reduced inflammation and symptom relief [1].
Who developed delgocitinib?
Toray Industries, Inc. is associated with the patent application US20140187534 concerning delgocitinib [1]. Toray is a Japanese multinational corporation that engages in various industries, including chemicals, textiles, and pharmaceuticals.
What are other JAK inhibitors for autoimmune diseases?
The development of JAK inhibitors for autoimmune diseases has led to several other drugs approved for use. These include tofacitinib, baricitinib, and upadacitinib, which are approved for conditions like rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis [4][5][6]. Each JAK inhibitor has a different selectivity profile for the JAK enzyme family, which can influence their efficacy and safety [4].
What is the difference between delgocitinib and other JAK inhibitors?
Delgocitinib is a pan-JAK inhibitor, meaning it targets multiple JAK family members (JAK1, JAK2, JAK3, and TYK2) [1]. Other JAK inhibitors may have varying selectivity profiles. For instance, tofacitinib primarily inhibits JAK1 and JAK3, while baricitinib inhibits JAK1 and JAK2 [4]. This difference in selectivity can lead to distinct therapeutic effects and side effect profiles. The specific clinical data and approved indications for delgocitinib will differentiate it from other JAK inhibitors in practice.
What are the potential side effects of JAK inhibitors?
JAK inhibitors, as a class, can be associated with certain side effects. These may include an increased risk of infections, including serious infections, as well as cardiovascular events and thrombosis [4]. Other potential side effects can involve changes in blood counts, liver enzyme elevations, and lipid abnormalities [4]. The specific side effect profile of delgocitinib would be detailed in its prescribing information once approved for marketing.
What is the regulatory status of delgocitinib?
The regulatory status of delgocitinib can vary by region and is subject to review by health authorities. As of its patent filing in 2014, it was in the investigational phase [1]. Further clinical trials and regulatory submissions would be necessary for its approval. Information regarding current regulatory approvals and ongoing clinical trials can be obtained from pharmaceutical company announcements and regulatory agency websites.
What are the clinical trials for delgocitinib?
Clinical trials are essential for evaluating the safety and efficacy of new drugs like delgocitinib. These trials typically involve multiple phases, from early-stage testing in small groups of people to later-stage studies in larger patient populations to confirm effectiveness and monitor side effects [7]. Information on ongoing or completed clinical trials for delgocitinib can be found in public clinical trial registries.
Sources:
[1] https://patents.google.com/patent/US20140187534A1/
[2] https://www.uspto.gov/patents/basics/deciphering-patent-terms
[3] https://drugpatentwatch.com/
[4] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-box-new-safety-warnings-updated-information-about-use-janus-kinase
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[6] https://www.nejm.org/doi/full/10.1056/NEJMra2020106
[7] https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-clinical-trials